SOURCE: Syneron Medical Ltd.

Syneron Medical Ltd.

November 11, 2009 09:36 ET

Syneron Debuts elure™ Advanced Dermal Whitening in Asia

HONG KONG--(Marketwire - November 11, 2009) - Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, today announced the commercial launch of the elure™ topical whitening products in several Asian markets.

Skin whitening is one of the fastest growing segments of the global beauty industry. The Asian market is estimated to be around US$18 billion per annum in size(1). The global whitening market is expected to grow over 10% annually(2), with major opportunities emerging from the rapidly expanding Asian markets.

The elure advanced dermal whitening product is the first scientifically proven enzymatic skin whitening treatment that targets and decomposes melanin to reveal a visibly lighter and exceptionally luminous skin tone. This product line is based on the a unique scientific discovery of a naturally occurring bio-active substance, Melanozyme™, working in cooperation with scientists in the field of biotechnology and enzymes and with international cosmetic experts.

Melanozyme acts to decompose the melanin in a clinically proven, fast and safe manner with no side effects. It is combined with a bio-activator to diminish the dark colored pigment in the skin. Unlike several other whitening products in the market, the elure product line does not contain Hydroquinine which may cause side effects such as skin redness and burning sensation.

"As a global leading provider of medical aesthetic devices, we are pleased to expand into the skin whitening arena with our established track record in technological innovation," said Shimon Eckhouse, Chairman of the Board at Syneron. "The elure treatment is designed to treat uneven discoloration associated with aging and sun damage, by gently eliminating the darker pigmentation when it appears at the upper layers of the skin, resulting in a whiter and brighter skin."

elure includes a complete range of skin products that have been researched and tested on all skin types. Studies have shown faster results when compared to other products in the market. Clinical studies(3) results were as follows when used twice a day for 28 days:

--  82% of the subjects demonstrated a significant decrease in their
    melanin index
--  91% of the subjects showed an overall improvement in fairness and skin
    tone
    

The new product line will be available for sale in Q1 2010 at dermatologists', beauty salons and spas throughout Asia.

About Syneron

Syneron Medical Ltd. (NASDAQ: ELOS) is a recognized world leader in the non-invasive aesthetic device market. The company develops, manufactures and distributes medical aesthetic devices that are powered by proprietary, patented elos™, a combined-energy technology of bi-polar radio frequency and light. With its undisputed pioneering approach to aesthetic treatments for both the face and body, Syneron has now ventured out into one of the largest in-demand applications, skin whitening. elure products are based on a breakthrough technology which offers skin whitening at no risk, with proven clinical results in a considerable shorter time when compared to other modalities available in the market. Syneron has offices and distributors throughout the world, including a headquarters in Israel; a North American headquarters in Irvine, California; an Asia Pacific headquarters in Hong Kong and a Syneron subsidiary in China. Additional information can be found at www.syneron.com

Issued on behalf of Syneron by Newell Public Relations.

(1) Source: in-cosmetics Asia
(2) Source: Euromonitor International
(3) Asian trial was managed by DermScan Laboratories, France

Contact Information

  • For more information please contact:

    Anna Tam
    Syneron Medical (HK) Ltd.
    Tel:+ 852 2543 4326
    Email: Email Contact

    Bertha Ung
    Newell PR
    Tel: +852 2117 5032
    Email: Email Contact

    Dora Chow
    Newell PR
    Tel: +852 2117 5022
    Email: Email Contact